Global RNA expression profiling of k13-edited mutant and isogenic wild-type Plasmodium falciparum malaria parasites during the parasite's intra-erythrocytic developmental cycle and the parasite's response to dihydroartemisinin (DHA).
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA635102 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:K13 mutations are causal for artemisinin resistance in Plasmodium falciparum human malaria. The objective of our study is to characterize gene expression signatures associated with K13 mutations by comparing transcriptional profiles and response to DHA of K13 mutant (C580Y, R539T) and isogenic wild-type lines that were generated by zinc finger nuclease (ZFN) based editing in a long-term adapted (Dd2) and a contemporary laboratory-adapted clinical isolate (Cam3.II).
2020-11-01 | GSE151189 | GEO
Project description:Control of malaria is threatened by emerging parasite resistance to artemisinin drug (ART) therapies. The molecular details of how Plasmodium malaria parasites response to ART and how this relates to resistance is not clear. To determine how parasites respond to ART by altering gene expression, we performed a transcriptomic study of dihydroartemisinin (DHA) response in P. falciparum K1 strain and in P. berghei ANKA strain. Microarray data from DHA-treated P. falciparum trophozoite stage parasites were compared with data from other ART treatments. Genes with consistent changes in expression were identified, which includes notably down-regulation of cytosolic ribosomal protein genes. RNA-seq data revealed a similar pattern of transcriptomic change, although the pattern was much clearer in that more than one-third of P. falciparum trophozoite genes are differentially expressed with greater statistical support for down-regulation of ribosomal protein genes. The poor overlap of differentially-expressed genes between microarray and RNA-seq and less-well defined patterns for the former suggests that the accuracy of microarray is limited by technological bias. The trophozoite response to DHA is overall âring-likeâ and less âtrophozoite-likeâ, which is consistent with previous findings that Plasmodium can enter a quiescent ring-like state to resist ART. RNA-seq data from DHA-treated P. falciparum rings reveal a more muted response, although there is considerable overlap of differentially expressed genes with DHA-treated trophozoites. In contrast, P. falciparum schizonts are unresponsive to DHA, suggesting that the protective response acts mainly to arrest parasite development through the G2/M checkpoint. The transcriptional response of P. berghei to DHA treatment in vivo in infected mice is strikingly similar to the P. falciparum in vitro ring and trophozoite responses, in which ribosomal protein genes are notably down-regulated. These results suggest Plasmodium species respond to DHA in the same way. This knowledge could be applied to outwit the parasite to deliver more effective artemisinin therapies, and maybe hinder the development of drug resistance. Two condition drug-treatment experiment, Dihydroartemisinin vs. Vehicle control treatment with matched reference untreated controls. Biological replicates: 5 independently grown and harvested experimental culture replicates. One replicate of treatment/reference time-point per array.
2015-10-15 | E-GEOD-61536 | biostudies-arrayexpress
Project description:K13 mutations are causal for artemisinin resistance in Plasmodium falciparum human malaria. We characterized changes in protein abundance associated with K13 mutations during the parasite's 48h intra-erythrocytic developmental cycle by comparing protein expression profiles of K13 mutant (C580Y, R539T) and isogenic wild-type lines that were generated by zinc finger nuclease (ZFN) based editing in a laboratory-adapted clinical isolate (Cam3.II). For each parasite line, we harvested tightly synchronized ring and trophozoite parasites on two independent occasions, except for the C580Y line which was harvested only once at trophozoite stage.
2020-11-23 | PXD019612 | Pride
Project description:Control of malaria is threatened by emerging parasite resistance to artemisinin drug (ART) therapies. The molecular details of how Plasmodium malaria parasites response to ART and how this relates to resistance is not clear. To determine how parasites respond to ART by altering gene expression, we performed a transcriptomic study of dihydroartemisinin (DHA) response in P. falciparum K1 strain and in P. berghei ANKA strain. Microarray data from DHA-treated P. falciparum trophozoite stage parasites were compared with data from other ART treatments. Genes with consistent changes in expression were identified, which includes notably down-regulation of cytosolic ribosomal protein genes. RNA-seq data revealed a similar pattern of transcriptomic change, although the pattern was much clearer in that more than one-third of P. falciparum trophozoite genes are differentially expressed with greater statistical support for down-regulation of ribosomal protein genes. The poor overlap of differentially-expressed genes between microarray and RNA-seq and less-well defined patterns for the former suggests that the accuracy of microarray is limited by technological bias. The trophozoite response to DHA is overall “ring-like” and less “trophozoite-like”, which is consistent with previous findings that Plasmodium can enter a quiescent ring-like state to resist ART. RNA-seq data from DHA-treated P. falciparum rings reveal a more muted response, although there is considerable overlap of differentially expressed genes with DHA-treated trophozoites. In contrast, P. falciparum schizonts are unresponsive to DHA, suggesting that the protective response acts mainly to arrest parasite development through the G2/M checkpoint. The transcriptional response of P. berghei to DHA treatment in vivo in infected mice is strikingly similar to the P. falciparum in vitro ring and trophozoite responses, in which ribosomal protein genes are notably down-regulated. These results suggest Plasmodium species respond to DHA in the same way. This knowledge could be applied to outwit the parasite to deliver more effective artemisinin therapies, and maybe hinder the development of drug resistance.
2015-10-15 | GSE61536 | GEO
Project description:Control of malaria is threatened by emerging parasite resistance to artemisinin drug (ART) therapies. The molecular details of how Plasmodium malaria parasites response to ART and how this relates to resistance is not clear. To determine how parasites respond to ART by altering gene expression, we performed a transcriptomic study of dihydroartemisinin (DHA) response in P. falciparum K1 strain and in P. berghei ANKA strain. Microarray data from DHA-treated P. falciparum trophozoite stage parasites were compared with data from other ART treatments. Genes with consistent changes in expression were identified, which includes notably down-regulation of cytosolic ribosomal protein genes. RNA-seq data revealed a similar pattern of transcriptomic change, although the pattern was much clearer in that more than one-third of P. falciparum trophozoite genes are differentially expressed with greater statistical support for down-regulation of ribosomal protein genes. The poor overlap of differentially-expressed genes between microarray and RNA-seq and less-well defined patterns for the former suggests that the accuracy of microarray is limited by technological bias. The trophozoite response to DHA is overall “ring-like” and less “trophozoite-like”, which is consistent with previous findings that Plasmodium can enter a quiescent ring-like state to resist ART. RNA-seq data from DHA-treated P. falciparum rings reveal a more muted response, although there is considerable overlap of differentially expressed genes with DHA-treated trophozoites. In contrast, P. falciparum schizonts are unresponsive to DHA, suggesting that the protective response acts mainly to arrest parasite development through the G2/M checkpoint. The transcriptional response of P. berghei to DHA treatment in vivo in infected mice is strikingly similar to the P. falciparum in vitro ring and trophozoite responses, in which ribosomal protein genes are notably down-regulated. These results suggest Plasmodium species respond to DHA in the same way. This knowledge could be applied to outwit the parasite to deliver more effective artemisinin therapies, and maybe hinder the development of drug resistance.
2015-10-15 | GSE62133 | GEO
Project description:Control of malaria is threatened by emerging parasite resistance to artemisinin drug (ART) therapies. The molecular details of how Plasmodium malaria parasites response to ART and how this relates to resistance is not clear. To determine how parasites respond to ART by altering gene expression, we performed a transcriptomic study of dihydroartemisinin (DHA) response in P. falciparum K1 strain and in P. berghei ANKA strain. Microarray data from DHA-treated P. falciparum trophozoite stage parasites were compared with data from other ART treatments. Genes with consistent changes in expression were identified, which includes notably down-regulation of cytosolic ribosomal protein genes. RNA-seq data revealed a similar pattern of transcriptomic change, although the pattern was much clearer in that more than one-third of P. falciparum trophozoite genes are differentially expressed with greater statistical support for down-regulation of ribosomal protein genes. The poor overlap of differentially-expressed genes between microarray and RNA-seq and less-well defined patterns for the former suggests that the accuracy of microarray is limited by technological bias. The trophozoite response to DHA is overall “ring-like” and less “trophozoite-like”, which is consistent with previous findings that Plasmodium can enter a quiescent ring-like state to resist ART. RNA-seq data from DHA-treated P. falciparum rings reveal a more muted response, although there is considerable overlap of differentially expressed genes with DHA-treated trophozoites. In contrast, P. falciparum schizonts are unresponsive to DHA, suggesting that the protective response acts mainly to arrest parasite development through the G2/M checkpoint. The transcriptional response of P. berghei to DHA treatment in vivo in infected mice is strikingly similar to the P. falciparum in vitro ring and trophozoite responses, in which ribosomal protein genes are notably down-regulated. These results suggest Plasmodium species respond to DHA in the same way. This knowledge could be applied to outwit the parasite to deliver more effective artemisinin therapies, and maybe hinder the development of drug resistance.
2015-10-15 | GSE62132 | GEO
Project description:The objective of this study was to determine whether Dihydroartemisinin (DHA), a drug highly effective in treating malaria infection with good safety, could be repurposed for the treatment of skin fibrosis in systemic sclerosis (SSc). mRNA-seq of primary human fibroblast cultures from healthy donors treated with DHA or vehicle were performed. By KEGG and Reactome analysis, we identified autophagy was one of the most significantly enriched terms.
2020-12-03 | GSE162550 | GEO
Project description:The molecular mechanisms through which dihydroartemisinin (DHA) induces immunomodulation in vivo remain unclear. Herein, DHA-regulated proteins and their phosphorylation profiles were identified and characterized, in the spleens of mice, using proteomics and phosphoproteomic approaches. We found that DHA upregulates proliferation-associated protein (cyclin-dependent kinases, Ki67, and mini-chromosome maintenance and proliferating cell nuclear antigen) expression via modulation of mitogen-activated protein kinase (MAPK) - activator protein 1 (AP-1) signaling pathway activity. In addition, DHA promoted the proliferation of CD4 T naïve, proliferated CD25+CD4+ T-cells, and BrdU+ interferon (IFN)-γ-producing CD8+ T cells. These predicted mechanisms of action were then validated in a Plasmodium berghei ANKA-infected mouse model of malaria and a cyclophosphamide-induced immunosuppression model. Collectively, the findings of this study, for the first time, provide robust evidence that DHA induced the expansion of the splenic T-cell pool through MAPK-AP1 signaling. The data provided in-depth knowledge in the mechanism of DHA-mediated immunomodulation.
2022-05-29 | PXD030353 | Pride
Project description:In the context of artemisinin resistance, the objective of the project was to evaluate the role of apicoplast and mitochondrion pathways during the parasite quiescent state induced by dihydroartemisinin (DHA) treatment. We performed gene expression profiling analysis using data obtained from RNA-seq of artemisinin-resistant parasites in two conditions: DHA treatment or DMSO treatment (as control condition) at the ring stage (obtained by D-sorbitol synchronization).
2024-10-16 | GSE207610 | GEO
Project description:We establish a method to reprogram bulk multiple myeloma (MM) cancer cells into MM cancer stem cells (MMSCs) via heterochromatin modulation, which allows us to obtain sufficient functional MMSCs in an efficient manner. Characterization of these induced MMSCs demonstrates that the reprogrammed MMSCs possess the properties of cancer stem cells both phenotypically and functionally. To leverage this model therapeutically, we screened a panel of compounds, and identified dihydroartemisinin (DHA) as a potent anti-MMSCs drug both in vitro and in vivo. DHA induces anti-proliferation effects on MMSCs via nuclear lamina perturbation and chromatin structure alteration. Hi-C analysis reveals that DHA modulates chromatin architecture mainly at the compartmental level and TADs (topologically associating domains) level. The potent anti-MMSCs efficacy and the novel molecular insights establish the therapeutic rationale for DHA in overcoming therapy resistance caused by cancer stem cells.
2023-09-09 | GSE159209 | GEO